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Abstract
Background: Substance use is prevalent in South Africa and associated with poor HIV treatment outcomes, yet, it is
largely unaddressed in HIV care. Implementing an evidence-based, task-shared intervention for antiretroviral therapy
(ART) adherence and substance use integrated into HIV care may be a feasible and effective way to improve HIV
treatment outcomes and reduce substance use in this population.
Methods: Guided by the RE-AIM framework, a randomized, hybrid type 1 effectiveness-implementation trial (n = 60)
is being used to evaluate a peer-delivered intervention that integrates evidence-based intervention components,
including Life-Steps (problem solving and motivational skills for HIV medication adherence), behavioral activation to
increase alternative, substance-free rewarding activities in one’s environment, and relapse prevention skills,
including mindfulness. The comparison condition is enhanced standard of care, which includes facilitating a referral
to a local substance use treatment clinic (Matrix). Participants are followed for a period of 6 months.
Implementation outcomes are defined by Proctor’s model for implementation and include mixed methods
evaluations of feasibility, acceptability, and fidelity, and barriers and facilitators to implementation. Primary patient-
level effectiveness outcomes are ART adherence (Wisepill) and substance use (WHO-ASSIST and urinalysis); viral load
is an exploratory outcome.
Discussion: Results of this trial will provide important evidence as to whether peer delivery of an integrated
intervention for ART adherence and substance use is feasible, acceptable, and effective. Implementation outcomes
will provide important insight into using peers as an implementation strategy to extend task sharing models for
behavioral health in resource-limited settings globally.
Trial registration: ClinicalTrials.gov identifier: NCT03529409. Trial registered on May 18, 2018.
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Introduction
South Africa (SA) is home to the largest number of people
living with HIV (PLWH) in the world—approximately 7.7
million [1]. With limited antiretroviral therapy (ART) regi-
mens available in SA, there is high risk of ART nonadher-
ence and treatment failure [2]. Alongside the HIV
epidemic, there has been an alarming increase in sub-
stance use (SU) in SA [3, 4], though SU is largely unad-
dressed in HIV care. This is a “missed opportunity” for
maximizing HIV treatment, given that untreated, prob-
lematic SU is associated with worse ART adherence, lower
rates of viral suppression, and greater likelihood of HIV
transmission [5–9]. SU treatment utilization in SA is low;
only approximately 2.3% of individuals seeking care re-
ceive minimally adequate treatment [10]. Although inte-
grated services are more efficacious [11] and there is a
push towards integrated care models for PLWH in low
and middle-income countries (LMICs) [12] and in SA spe-
cifically [13], this is not a routine practice for ART adher-
ence and SU treatment in SA [14]. Implementation
science research is needed to understand how to feasibly,
effectively, and efficiently integrate SU treatment into HIV
care in SA.
In particular, sustainability must be considered, espe-
cially for LMICs. Given the lack of availability of trained
mental health and SU professionals in this setting, an im-
plementation strategy will require “task sharing” [15, 16].
Task sharing models include hiring and training less spe-
cialized health care workers, such as community health
workers (CHWs) or lay counselors, to deliver mental
health services under the supervision of more highly
trained professionals [17]. Task sharing mental health
treatment has largely focused on training lay adherence
counselors and CHWs and to a much lesser extent peers
[18, 19]. When considering scale-up of task-shared mental
health interventions, there are known implementation
barriers using lay adherence counselors and/or CHWs,
including high caseloads, already being burdened with
numerous clinical demands, as well as high levels of
stigma towards SU [20]. Peers add an ability to share lived
experience that can foster connection with patients and
potentially reduce stigma [21]. Indeed, formative work
leading up to this trial pointed to an overwhelming prefer-
ence for peer-delivered SU counseling [20]. Peer-delivered
SU interventions have been scaling in the USA and have
been shown to be efficacious for improving engagement
in care, reducing costly utilization, and improving SU out-
comes [22].
This trial builds upon prior and ongoing work in SA
that has largely, until recently, focused on efficacy (vs. im-
plementation) research for treating alcohol use among
PLWH [14, 23, 24]. The current trial builds upon these
prior studies in several ways, including (1) screening indi-
viduals who are also using other substances in addition to
alcohol; (2) targeting recruitment of individuals who are
struggling with ART adherence, engagement in care, and/
or viral suppression; (3) using a hybrid effectiveness-
implementation design; and (4) utilizing an implementa-
tion strategy of peer delivery as opposed to an HIV
counselor or CHW.
Trial objectives
The primary objective of this trial is to evaluate the ef-
fectiveness and implementation of an integrated, peer-
delivered SU and ART adherence intervention delivered
in HIV care in SA. This trial will contribute important
insight into the implementation strategy of using peers
in a task sharing model—specifically whether a peer-
delivered behavioral intervention for SU in HIV care will
be feasible, acceptable, and delivered with fidelity and
how this compares with prior evidence using other lay
health worker task sharing models.
Methods
This manuscript is in accordance with the Standard
Protocol Items: Recommended items to address in a
clinical trial protocol and related documents (SPIRIT)
guidelines. See Additional file 1 SPIRIT checklist.
Trial design
This study is using a hybrid type 1 effectiveness-
implementation design [25], guided by RE-AIM [26, 27],
given its inclusion of patient- and provider-level out-
comes and prior application in sub-Saharan Africa [28,
29]. The intervention being evaluated is a combination
of efficacious treatment components, but because it had
not previously been delivered in this setting, we elected
to use a hybrid type 1 design; however, a primary em-
phasis of this trial is on the implementation in this new
Contributions to the literature
 Project Khanya will extend the existing literature by
improving our understanding of the implementation of
peer-delivered behavioral interventions for substance use
and HIV medication adherence in a resource-limited setting
with one of the greatest HIV burdens globally.
 Implementation science methods are needed to evaluate
task sharing models in global mental health.
 Resource-limited settings with the greatest HIV burden face
unique implementation barriers.
 A peer-delivered integrated behavioral intervention such as
the one evaluated in Project Khanya may be a feasible,
acceptable, efficient, and scalable approach to extending the
reach of substance use care for people living with HIV
globally.
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context. Implementation outcomes were defined based
upon Proctor’s model and recommendations for early
implementation assessments [30]. See Table 1 for a de-
scription of the RE-AIM constructs and implementation
outcome measurements in the current trial. This study
is a randomized controlled trial (RCT) with two parallel
arms: enhanced standard of care (ESOC) and the active
behavioral intervention (locally named “Khanya”), which
includes a combination of efficacious intervention com-
ponents locally adapted for this setting (see descriptions
below).
Participants and study procedures
The study flow CONSORT diagram is illustrated in
Fig. 1. Patients are recruited from an HIV clinic in
Khayelitsha, a peri-urban area of Cape Town that is pre-
dominantly Black African and isiXhosa speaking with
the highest HIV prevalence in SA’s Western Cape Prov-
ince [32]. Potentially eligible and interested patients are
approached by study staff for screening. All patients are
informed that study participation will in no way affect
their treatment at the clinic. Screened participants who
meet study inclusion criteria (see below) complete in-
formed consent processes prior to baseline by a trained
study research assistant, including a release of relevant
medical information, and then complete a baseline as-
sessment. The baseline assessment includes a battery of
measures related to HIV infection history, medication
adherence, and current and past SU. Participants also
begin monitoring their ART adherence using Wisepill
[33], a real-time, wireless electronic adherence monitor-
ing device. Randomization to intervention condition oc-
curs 2 weeks after the baseline assessment to establish a
baseline level of ART adherence. At randomization, par-
ticipants are randomly assigned (1:1) to either ESOC or
Khanya using a computer-generated chart in the
randomization module on REDCap [34]. The study staff
clicks “randomize” in REDCap, and the participant’s
condition is revealed and cannot be changed. Partici-
pants then complete the following major assessment
time points: mid-point, post-treatment, and 6-month
follow-up. See Additional file 2 for the schedule of en-
rollment, assessments, and interventions. The post-
randomization assessments are conducted by a research
assistant who is blinded to participant condition1 with
no a priori circumstance under which unblinding is per-
mitted. All participants receive ZAR 150 (~ $10 USD)
grocery voucher for major assessments. Participants do
not receive financial incentives to attend therapy ses-
sions beyond reimbursing travel costs incurred in order
to attend therapy visits (ZAR 50; ~$3 USD).
Eligibility criteria
Eligibility criteria include (1) HIV positive and on ART;
(2) 18–65 years of age; (3) moderate SU measured by the
WHO Alcohol, Smoking, and Substance Involvement
Table 1 RE-AIM framework applied to study outcomes
Dimension Description Outcome assessment
Reach Intervention ability to reach participants who have
both SU problems and ART nonadherence
• % of patients screened who meet eligibility criteria for study enrollment
Effectiveness ART adherence (primary) • Number of doses missed divided by the number of prescribed doses
(measured via Wisepill)
SU (primary) • Urinalysis (yes/no) and self-reported total score on the WHO-ASSIST score
Viral suppression (exploratory) • Viral load copies per ml of blood
Adoption Provider and organization perceptions of
feasibility/acceptability and future uptake
• Qualitative interviews with providers and organizational leadership based on
RE-AIM to assess perceptions and likelihood of uptake following the trial;
longer-term adoption to be assessed in the subsequent trial following from
this pilot study
Implementation Feasibility • Pragmatic implementation science measure based on RE-AIM (14-item feasi-
bility subscale) [31]
• % assigned to the intervention who agree to enroll
• Qualitative interviews with patients structured based on RE-AIM
Acceptability • Pragmatic implementation science measure based on RE-AIM (15-item ac-
ceptability subscale) [31]
• Retention: % attending ≥ 1 session, % attending ≥ 75% of sessions, uptake of
booster sessions, and % who dropped out of the intervention
• Qualitative interviews with patients structured based on RE-AIM
Intervention fidelity • Independent rater and interventionist self-report on randomly selected 20%
of intervention sessions
Maintenance Provider continued usage of Khanya to treat co-
occurring SU and ART nonadherence
• To be evaluated in the subsequent trial following from this pilot study
1Blinded assessor was introduced after ten participants completed the
post-treatment assessment and one participant completed the 6-month
follow-up due to staffing constraints at study initiation.
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Screening Test (WHO-ASSIST) [35] (alcohol ≥ 11 or
other SU ≥ 4, indicating moderate risk of health and other
problems); and (4) ART nonadherence in the past 3
months, as measured by either (a) missing at least one re-
fill of ART, (b) reinitiating first-line treatment, (c) being
on second-line treatment, or (d) having a detectable viral
load. Exclusion criteria are (1) severe opiate use (WHO-
ASSIST score > 26) given that opiate substitution therapy
may not be available and a higher level of care may be
needed, (2) severe alcohol dependence symptoms that
may warrant medical management of withdrawal symp-
toms, (3) active uncontrolled major mental illness (e.g.,
psychosis, mania) that interferes with study participation,
(4) inability to provide informed consent and/or complete
procedures in English or isiXhosa, (5) in the third
trimester of pregnancy during screening or baseline, or (6)
currently enrolled in Matrix or another SU treatment pro-
gram or study focused on ART adherence or SU.
Interventions
ESOC
Given the implementation science focus, we elected to
use a version of standard of care (SOC) as our study
comparator. SOC for the treatment of SU, if and when
detected in HIV care in SA, is a referral to a local SU
treatment clinic. In Khayelitsha, there is a city-funded
SU treatment program co-located at the HIV care study
site, which follows the Matrix model [36, 37], an
evidence-based 16-week program to treat SU. Although
the two sites are not connected from the inside, a Matrix
Fig. 1 CONSORT diagram
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treatment center shares a driveway and a wall with the
clinic at which this study is taking place. Yet, there is
evidence from our preliminary work from this study that
clinic patients may not be aware of Matrix [20]. There-
fore, we enhance SOC (ESOC) by facilitating screening
for SU using the WHO-ASSIST and support the referral
to Matrix, which includes offering to accompany partici-
pants to the Matrix clinic to schedule an intake, provid-
ing a direct referral, and following up on the referral at
each subsequent study visit.
Khanya intervention
The Khanya intervention is a six-session, peer-delivered
intervention that includes a combination of efficacious
intervention components for ART adherence and SU, in-
cluding Life-Steps (problem solving and motivational skills
for HIV medication adherence) [38], motivational inter-
viewing (MI) to explore readiness to change SU and adher-
ence behaviors, behavioral activation to increase alternative,
substance-free rewarding activities in one’s environment
[39, 40], and relapse prevention skills, including mindful-
ness [41, 42]. Formative qualitative work [20] was used to
adapt the intervention content and implementation strategy
to ensure the relevance of the efficacious intervention con-
cepts (e.g., mindfulness, values) to the local culture and to
promote feasibility and acceptability of the approach. When
participants present for each intervention session, a graph
of their ART adherence from the Wisepill device is printed
from the server prior to the session and used to aid the
discussion of challenges to ART adherence. Participant SU
is assessed by a research assistant (not the interventionist)
using the Timeline Follow-Back (TLFB) prior to the begin-
ning of each session. The TLFB is used to guide the review
of SU in-session and discussed together using an MI
approach to explore patterns of use in line with the partici-
pant’s goal around SU; this continues in each session as the
participant learns skills to address SU, its interference with
ART adherence, and other substance-related problems.
Each session lasts approximately 45min to 1 h and builds
upon prior session content. Each session ends with a brief
mindfulness exercise, and participants are also given a CD
with audio recordings of the brief mindfulness exercises in
isiXhosa that are covered at the end of each session. Home
practice of the intervention skills is assigned between
sessions and reviewed at each subsequent session. All
sessions are audio recorded for fidelity monitoring. Partici-
pants are also offered up to six optional booster sessions
that focus on continued practice of skills and relapse
prevention. See our team’s prior research [43–45] for
greater detail on the intervention components.
Implementation strategies
Two implementation strategies that emerged from our
formative work included the need for (1) peer delivery of
the intervention (i.e., a lay counselor with lived experi-
ence with SU and/or HIV) and (2) the use of a flipchart
to promote fidelity [20]. We tailored the approach for
peer delivery by building flexibility into our intervention,
training, and supervision procedures to allow for self-
disclosure to accommodate the unique perspective of a
peer interventionist and adapted our fidelity assessment
to also include these elements. Regarding the flipchart,
the ultimate aim is to maximize fidelity while also en-
hancing participant engagement and comprehension
(see Fig. 2). While the participant sees mostly visual
depictions of the concepts, the interventionist has a
guide on the content to deliver and is able to maintain
eye contact while following the structured guide for
content delivery.
Peer interventionist training
Interventionist training was led by a US-based clinical
psychologist (JFM) in SA over 5 days. The training was
guided by the flipchart and included a combination of di-
dactic training, interactive, experiential learning of inter-
vention components, including developing one’s own
mindfulness practice, and role plays. Following the 5-day
in person training, ongoing training and supervision was
conducted weekly via videoconferencing and included re-
flections on one’s own mindfulness practice and personal
experience with behavioral activation and feedback on role
played sessions. Role plays of the full intervention were
conducted with five mock participants and video recorded
to allow for ongoing training and fidelity monitoring to
determine readiness to begin delivering the intervention.
Supervision
The interventionist receives 1 h of weekly supervision
from a US-based PhD-level psychologist with expertise in
behavioral interventions for medication adherence and
substance use. Supervision sessions are held over Webex,
a secure video teleconference service. The interventionist
translates one session per week from isiXhosa to English
for the supervisor to listen to and provide feedback (separ-
ate from the randomly selected sessions that are translated
for fidelity ratings). Supervision is focused on fidelity, non-
specific clinical skills of the interventionist (e.g., being sup-
portive and nonjudgmental, appropriate self-disclosure),
time management, and strategies to reduce burnout.
Study measures
Implementation outcomes
Guided by RE-AIM [26, 27] and Proctor’s model [30],
we are assessing early implementation outcomes, includ-
ing a mixed methods evaluation [46] of acceptability and
feasibility, and fidelity of peer delivery.
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Acceptability, defined as the tolerability or satisfaction
of the approach [30], is assessed using two quantitative
assessment measures: (1) a 15-item subscale of a prag-
matic, quantitative assessment based on RE-AIM [31]
developed by the Applied Mental Health Research group
(AMHR) at Johns Hopkins University [31] and (2)
quantitative metrics of patient attendance, uptake, and
retention in the intervention. The AMHR pragmatic,
quantitative assessment [31] is a validated measure
assessing key implementation domains for a mental
health intervention in a LMIC. Sample items on the
acceptability subscale include “Did you feel satisfied with
the program’s services?” and “Did you enjoy learning
skills from the program?” Psychometric properties of the
scale show good internal consistency (∝ = .89) and test-
retest reliability (rho = .70).
Feasibility, defined as the fit or utility of the intervention
or suitability and practicability for this setting [30], is also
being assessed using two quantitative assessments: (1) the
14-item feasibility subscale of the AMHR pragmatic
assessment measure based on RE-AIM [31] and (2) the
percentage assigned to the intervention who agree to en-
roll in the intervention. The feasibility subscale also shows
good psychometric properties (internal consistency
∝ = .85; test-retest reliability rho = .79). Sample items from
the feasibility subscale include “Have you been able to at-
tend the sessions of the program without difficulty?” and
“Did you have enough money to pay for transport to get
to the program sessions?” Secondly, we will compare the
rates of patient enrollment and participation across condi-
tions with other similar pilot trials [47, 48].
To supplement the quantitative assessments of feasi-
bility and acceptability, qualitative interviews with up to
30 participants are also assessing perceptions of accept-
ability and feasibility of the intervention, as well as bar-
riers and facilitators to implementation. Qualitative
interview guides are based upon Proctor’s model for im-
plementation outcomes [30, 49] and the RE-AIM
Fig. 2 Depiction of flipchart implementation strategy to promote fidelity in task sharing model
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framework [26, 27]. We are using the qualitative inter-
views to gain more specificity on which elements of the
intervention are acceptable and feasible, as well as elicit
participant feedback on ways to improve these imple-
mentation outcomes going forward.
Fidelity is being assessed two ways: independent rater
and interventionist self-report. The independent rater is
listening to a randomly selected subset (20%) of interven-
tion sessions that are translated from isiXhosa to English.
A 15- to 19-item fidelity assessment was developed for
each session that includes an assessment of whether each
core intervention content component was delivered. At
the end of each session, the interventionist completes an
identical self-report form assessing her level of fidelity to
the intervention. In addition to rating content, the inde-
pendent rater assesses sessions for (a) appropriate self-
disclosure given the peer interventionist implementation
strategy; (b) presence of actively stigmatizing behaviors;
and (c) therapeutic common factors including exhibiting
warmth and non-judgmental attitudes, which were
adapted from prior research on cross-cultural common
factors [50].
Effectiveness outcomes
ART adherence is assessed using Wisepill, a real-time,
wireless electronic adherence monitoring device previ-
ously used in clinical research in sub-Saharan Africa to
assess ART adherence [33]. Wisepill uses cell phone
technology to transmit a real-time signal to a web server
when the pill box is opened. Participants do not need to
come into the clinic for the study to obtain readings. A
dose is counted as “taken” if the box is opened ± 2 h
from the prescribed time. As has been conducted in
prior adherence research (e.g., [51, 52]), adherence will
be measured as the number of doses missed divided by
doses prescribed between randomization and the post-
treatment assessment. The 2-week period from baseline
to randomization is the baseline adherence measure.
SU is assessed via both a biological measure (urinalysis)
and self-report. Urinalysis is conducted at all-time points
using the Confirm BioSciences rapid detect 6-panel urine
tests (cocaine, marijuana, amphetamines, opiates, phencyc-
lidine, and alcohol). Urinalysis is supplemented with man-
drax testing (a commonly used sedative in the area) using
the Methaqualone urine rapid test stick. The WHO-
ASSIST, a self-report assessment of SU (alcohol, cannabis,
cocaine, opiates, amphetamines, hallucinogens, and other
drugs), is administered at screening, when substance use
risk in the past 3months is assessed. At the post-treatment
and the follow-up assessments, alcohol and drug use are
assessed since the prior assessment. It categorizes individ-
uals into low (0–3 for illicit drugs/0–10 for alcohol), mod-
erate (4–26 for illicit drugs/11–26 for alcohol), or high risk
(> 26) for substance use-related problems. The use of the
WHO-ASSIST in primary care has been validated in SA
[35]. To supplement the WHO-ASSIST, we also administer
the TLFB to assess the frequency of alcohol and/or drug
use in the past 2 weeks at each assessment. To promote ac-
curate recall of the quantity of alcohol use on the TLFB,
participants are aided by the use of empty, locally
recognizable alcohol containers that reflect the commonly
used forms of alcohol in this population.
Viral suppression, which is measured as the number of
HIV viral copies per ml of blood, is extracted from par-
ticipants’ medical record at each assessement. If viral
load results are not available within 3 months of the
baseline assessment or 30 days of the two follow-up as-
sessments, participants undergo a separate blood draw
for viral load assay at no cost to the patient. Blood sam-
ples are stored at the University of Cape Town and
tested by the National Health Laboratory Service.
Power considerations and sample size calculations
The main analysis on which the sample size calculation
for the quantitative analysis was based is the effect of the
experimental intervention vs. ESOC on ART nonadher-
ence at post-treatment. Previous objective measures of
ART adherence in substance using populations have esti-
mated average adherence rates of approximately 55% with
a standard deviation of 25% [53–55]. Assuming similar
characteristics in ESOC and based on a sample size of 30
in each arm (recommended as the upper limit sample size
for pilot RCTs [56] and pilot hybrid type 1 effectiveness-
implementation designs [25, 57]), we will have 80% power
to detect an 18% difference in objectively measured ART
adherence between study arms using a two-sided test with
an alpha level of .05. For qualitative analyses, as recom-
mended in qualitative research [58], proposed sample sizes
are estimates of the number of interviews needed to reach
theoretical saturation.
Data management and data analysis
Quantitative data are collected using the REDCap inter-
face on a tablet. Data are reviewed twice for quality assur-
ance including checking consistency of participant
responses and ensuring that reported values fall within the
range of possible values. TLFB is administered using a
hardcopy calendar to allow for visual aids to guide partici-
pant recall, and these data are later entered into REDCap
and double checked for accuracy. Wisepill data are stored
on the Wisepill server. Wisepill devices are checked
weekly on the server to ensure devices are operational.
Descriptive statistics will be generated to evaluate im-
plementation outcomes. Total scores from the accept-
ability and feasibility subscales of the AMHR pragmatic,
implementation assessment [31] will be created; these
scores, alongside data obtained on provider fidelity to
the intervention and patient participation and retention,
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will first be evaluated descriptively. The means and
standard deviation of provider fidelity at each session
will be calculated. Average session fidelity will be com-
pared with similar lay counselor delivered interventions
implemented in SA and peer-delivered interventions in
the US; similarly, the percentage of patients participating
and retained in the intervention will be described and
compared with similar pilot studies [23, 59].
Data from individual interviews to assess implementa-
tion outcomes will be analyzed iteratively and follow
descriptive qualitative thematic analysis [60]. Guided by
RE-AIM and Proctor’s model for defining implementation
outcomes, initial concepts related to the central research
questions listed will be identified based on the semi-
structured interview guide. Concepts will be used to
develop a codebook consisting of a label, a definition, and
illustrative quotes from the data. All transcripts will be
coded independently by two research assistants. Final
themes will be agreed upon and inter-rater reliability of
coding assessed.
Following recommendations of mixed methods designs
[46], we will integrate findings from the qualitative and
quantitative methods using a convergent QUANT + qual
mixed methods design to assess implementation outcomes
[46]. Specifically, themes from the qualitative interviews will
be compared with the quantitative descriptive data on feasi-
bility and acceptability, assessing for both convergence and
divergence.
Quantitative longitudinal analysis will examine
changes in ART nonadherence, SU, and viral load from
baseline to post-treatment between the conditions. If
appropriate after examining descriptive data, normality,
and assumptions, t tests may be used to compare
continuous variables (e.g., age, ART nonadherence) and
Fisher’s exact test may be used to compare categorical
variables (e.g., gender, urinalysis). If the appropriate stat-
istical assumptions are met after examining distributions
of main outcome variables, longitudinal data analysis
using generalized linear mixed models (GLMM) may be
used to compare the two study arms over time. This
approach increases power by including all available data
points. We will adjust the analyses for relevant baseline
demographic characteristics (e.g., gender, age) for each
analysis and clinical differences that exist between the
two treatment arms. Intent-to-treat analyses will be
utilized, where all individuals will be analyzed according
to the condition to which they were randomized.
Ethical considerations and trial management
This study is approved by the University of Cape Town
(UCT) Human Research Ethics Committee (HREC). Data
are de-identified by using participant ID numbers (not
names) on all study materials. The document linking
participant identifiable information (e.g., names, phone
numbers) is stored on a secure institutional server, pass-
word protected, and only accessible to the study staff who
need access to this information to perform the study
duties.
This study has oversight by a Data Safety and Moni-
toring Board (DSMB). The DSMB meets annually to re-
view data collection procedures and ensure the scientific
and ethical rigor of the study is maintained. The DSMB
for this trial is comprised of three leading scientists who
have expertise in behavioral interventions, HIV, sub-
stance use, implementation science, and SA. The DSMB
members are independent of the sponsor without
competing interests for providing rigorous scientific and
ethical oversight. There are no a priori stopping rules for
discontinuing or modifying provision of the experimen-
tal intervention, although our DSMB has this right and
responsibility.
We collect information on adverse events that are experi-
enced by enrolled participants. Adverse events are classified
serious/non-serious, related/unrelated to the study inter-
vention, and expected/unexpected. All serious adverse
events (i.e., any event considered to be fatal, immediately
life-threatening, permanently or substantially disabling,
requiring or prolonging inpatient hospitalization, or any
congenital anomaly) are reported to UCT HREC within 24
h. We report all adverse events to our DSMB committee
yearly.
Key ethical considerations in this trial include protect-
ing the confidentiality and well-being of PLWH and SU.
We closely monitor and screen for medically compli-
cated withdrawal symptoms for patients with severe
alcohol use who are reducing their alcohol intake as part
of the intervention. We maintain a close relationship
with the co-located Matrix substance use treatment
facility and the medical officer at the clinic to ensure
patient safety throughout the trial.
All protocol modifications are submitted as ethics
amendments to the UCT HREC. Any major protocol
modifications will be reflected on ClinicalTrials.gov.
Participants are re-consented following any protocol
modifications that would impact their participation in
the study, and the UCT HREC approves whether it is
necessary to re-consent patients if a major protocol
amendment is requested.
Discussion
Given the prevalence of SU among PLWH in SA and
interference with HIV care outcomes across the
continuum [5–7, 9, 61], it is crucial to identify how to
integrate and implement evidence-based interventions to
treat substance use in HIV care in SA. Identifying inter-
vention components that can be feasibly and sustainably
delivered using a task sharing model is essential, as there
are significant workforce shortages for behavioral health
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interventions in SA and other LMICs [15, 62]. Task
sharing efforts in SA and elsewhere to date have largely
involved task sharing with lay counselors, such as lay
adherence counselors or CHWs, as opposed to peers
[15, 16, 18, 19]. This trial will contribute new knowledge
about the effectiveness and implementation of a peer-
delivered intervention using a task sharing model. This
study will allow us to gain understanding regarding the
feasibility, acceptability, fidelity, and effectiveness of this
peer-delivered approach and how these implementation
and effectiveness outcomes compare with other lay
health worker-delivered task-shared substance use inter-
ventions [18, 19]. An integrated intervention that simul-
taneously addresses substance use and ART adherence
offers a parsimonious approach if feasible for peer
delivery. As the SA Department of Health refines their
strategy for integration of behavioral health services into
primary health care facilities, findings may have import-
ant implications to understand what may be effective
and feasible in this context.
Potential challenges in this trial include difficulties with
recruiting and retaining patients who are struggling with
SU, ART nonadherence, and engagement in care. By pri-
oritizing recruitment of individuals who have already
demonstrated challenges with engagement in care, we are
more likely to recruit individuals who will have greater
challenges also in engaging in study-related appointments
and are difficult to retain. Further, to date, approximately
40% of participants have not owned a cell phone, which
makes tracking and retaining participants more
challenging. Starting from the point of screening through
the 6-month follow-up assessment, retaining this hard-to-
reach population is an important priority in this trial,
while also balancing real-world implementation that may
have limited resources to track and retain difficult popula-
tions. Efforts to address these anticipated challenges
include identifying participants who we are struggling to
retain during weekly team supervision and collecting
contact numbers for two people who are likely to know
the whereabouts of the participant.
Design considerations and future directions
There are numerous design considerations and decisions
that reflect our dual focus on both effectiveness and im-
plementation. For instance, we elected to include booster
sessions in our trial design based upon feedback from par-
ticipants and interventionist observation that additional
skill practice would be needed to sustain behavior change,
especially in light of fluctuating motivation. However, we
also recognize the need to prioritize brevity in our inter-
vention design to ultimately have an intervention package
that will enhance the probability of policy uptake within
SA’s Department of Health. Thus, we elected to offer
optional booster sessions with no financial incentives to
provide the option to reinforce ongoing skill practice and
relapse prevention and evaluate uptake of these optional
booster sessions as an additional measure of acceptability.
Primary limitations relate to this being a pilot trial, in-
cluding a small sample size and relatively short-term
follow-up period. There are also limitations when
considering future scale-up of the intervention, including
reimbursement for transport costs and financial incen-
tives provided for participating in research assessments
and the fact the interventionist was hired to deliver the
intervention and was not balancing other clinic responsi-
bilities. This trial is a first step towards evaluating
whether this intervention has potential for future scale-
up. If it proves to be effective in this setting and early
implementation outcomes are promising, next steps
would require a larger trial to evaluate longer-term
effectiveness and implementation outcomes, including
cost effectiveness, maintenance, and sustainability. Fur-
ther, these outcomes must be assessed at the provider
and organizational levels using a greater number of
clinic sites and peer interventionists in a future cluster
randomized clinical trial. Ultimately, our aim is to de-
velop and evaluate an intervention and implementation
strategy that can be scaled up in SA and other LMICs to
expand access to evidence-based HIV and behavioral
health care in resource-limited primary care settings.
Dissemination plan
The results of this study will be published after all data
is collected, cleaned, and analyzed, and the results will
be updated in ClinicalTrials.gov within 1 year of the pri-
mary completion date. We will also update NIH on the
study results in annual progress reports to NIDA. Add-
itionally, we will report back on the study results to the
City of Cape Town Health Department, including by
holding forums for HIV and SU treatment to share re-
sults with clinical providers, patients, and staff.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s43058-020-00004-w.
Additional file 1. SPIRIT Checklist.
Additional file 2. Schedule of enrollment, intervention, and
assessments.
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